<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>d </td><td>Date:</td><td>September 10, 2012</td></tr></table>

# 510(k) Substantial Equivalence Determination Decision Summary

A. 510(k) number: K122019

Assay used for the qualitative detection of Streptococcus pyogenes.

C. Measurand: Segment of the Streptococcus pyogenes genome

a

E. Applicant: Meridian Bioscience, Inc. 3471 River Hills Drive, Cincinnati, OH 45244 USA

F. Propriety and Established Names: illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay illumigene® Group A Streptococcus (Group A Strep) External Control Kit

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>xra} Regulation Section</td><td rowspan=1 colspan=1>\fra}$Panel</td></tr><tr><td rowspan=1 colspan=1>OYZ, Group A Streptococcus Nucleic AcidAmplification Assay System</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR § 866.3740</td><td rowspan=1 colspan=1>Microbiology (83)</td></tr></table>

# H. Intended Use:

![](images/45dee8ffe49b805b7632083fccacab4a49cc2ff535fb34fe00f719e14216334c.jpg)

1.Intended use(s):

The illumigene® Group A Streptococcus (Group A Strep) assay, performed on the illumipro- ${ \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla }$ , is a qualitative in vitro diagnostic test for the detection of Streptococcus pyogenes (Group A $\beta$ -hemolytic Streptococcus) in throat swab specimens.

l to detect Streptococcus pyogenes by targeting a segment of the Streptococcus pyogenes genome. Results from the illumigene Group A Strep assay can be used as an aid in the diagnosis of Group A Streptocal pharyngitis. The assay is not intended to monitor treatment for Group A Streptococcus infections.

iGr not intended for point-of-care use.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 Illumigene® Group A Streptococcus (Group A Strep) DNA Amplificatlon Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td rowspan="2">d</td><td>Date:</td><td>September 10, 2012</td></tr><tr><td></td><td></td></tr></table>

# Indication(s) for use:

The illumigene® Group A Streptococcus (Group A Strep) assay, performed on the illumipro- ${ \bf \nabla } \cdot { \bf \nabla } \mathbf { \Omega } ^ { 0 }$ ,is a qualitative in vitro diagnostic test for the detection of Streptococcus pyogenes (Group A $\beta$ -hemolytic Streptococcus) in throat swab specimens.

The illie Grou Sre ssytilizes o-ediatsteral DA plifiationLAMP ecl to detect Streptococcus pyogenes by targeting a segment of the Streptococcus pyogenes genome. Results from the illuigee Group A Strep assay can be used as an aid in the diagnosis of Group A Streptococcal pharyngitis. The assay is not intended to monitor treatment for Group A Streptococcus infections.

G   t not intended for point-of-care use.

3.Special Conditions for use statement(s):

For Prescription Use Only • The device is not intended for point-of-care use

4. Special instrument requirements:

illumipro- $\hbar ^ { \mu }$ Automated Isothermal Amplification and Detection System

# I. Device Description:

The illumigene Molecular Diagnostic Test System is comprised of the ilumigene® Group A Group A Strep DNA Amplification Test Kit, the illumigene® Group A Strep External Control Kit and the illumipro- ${ \mathfrak { 1 0 } } ^ { m }$ Automated Isothermal Amplification and Detection System.

Tl presence of Streptococcus pyogenes (Group A beta-hemolytic Streptococcus) in throat swab specimens. Each ile Groass  psl mpl reationprau eativ ona loureTeDevneaTe Tu TrntTuTar nConl savailalealpltionheat-eaD amplification occurs in the illumigene Test Device.

Th lhe  Go v n Con faciitatipltion  rt Whe  prent h r a seen   a sequence of the S. pyogenes genome is amplified and magnesium pyrophosphate is generated. Magnesium of the reaction solutions at the assay Run Start (Signalinitial, Si) and at the assay Run End $\{ \mathsf { S i g n a l } _ { \mathsf { H n a l } } , \mathsf { S } _ { \mathsf { f } } \}$ The illumipro10 calculates the change in light transmission between Run End and Run Start $( S _ { f } ; S _ { i } )$ and compares the ratio to a fixed cut-off value for disposition of results.

Fixed cut-off values for the TEST chamber are used to report sample results. TEST chamber $\mathsf { S } _ { \mathsf { f } } { : } \mathsf { S } _ { \mathsf { j } }$ ratios less than $82 \%$ are reported as 'POSITIVE'; TEST chamber $S _ { f } : S _ { j }$ ratios greater than or equal to $82 \%$ are reported as 'NEGATIVE'. lva i al y. CONTROL chamber $\mathsf { S } _ { \mathsf { f } } { : } \mathsf { S } _ { \mathsf { i } }$ ratios less than $90 \%$ are considered valid and allow for reporting of TEST chamber results (POSITIVE, NEGATIVE). CONTROL chamber $\mathsf { S } _ { \mathsf { f } } { : } \mathsf { S } _ { \mathsf { i } }$ ratios greater than or equal to $90 \%$ are considered invalid and prevent reporting of TEST chamber results. Invalid CONTROL chamber reactions are reported as INVALID'. Nlap ensure amplification is not inhibited, reagents are performing as intended and that sample processing was performed appropriately.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 Illumigene® Group A Streptococcus (Group A Strep) DNA Amplificatlon Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td rowspan="2">id Sci.s S.</td><td>Date:</td><td>September 10, 2012</td></tr><tr><td></td><td></td></tr></table>

T   i Reagent u nconuction wihe illiee Sample reaationAppratus /egative ontrol a in operator performance that may lead to test errors.

# J. Substantial Equivalence Information:

1. Predicate device name(s): GEN-PROBE® Group A Streptococcus Direct Test; Catalog 103890

2. Predicate 510(k) numbers: K924715

3.Comparison with predicates:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DEVICEillumigene  Group A Streptococcus</td><td colspan="1" rowspan="1">PREDICATEGEN-PROBE® Group A Streptococcus DirectK924715</td></tr><tr><td colspan="3" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">Test Format</td><td colspan="1" rowspan="1">Molecular-based Amplification Assay</td><td colspan="1" rowspan="1">Molecular-based Direct Assay</td></tr><tr><td colspan="1" rowspan="1">Target</td><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">Streptococcus pyogenes</td></tr><tr><td colspan="1" rowspan="1">Specimen Types</td><td colspan="1" rowspan="1">Throat Swab</td><td colspan="1" rowspan="1">Throat Swab</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self contained and automated</td><td colspan="1" rowspan="1">Self contained and automated</td></tr><tr><td rowspan="3">Meridian # Bioscience, Inc.</td><td colspan="2">K122019 illumigene® Group A Streptococcus (Group A Strep) DNA Amplfication Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>Iied </td><td>Date:</td><td>September 10, 2012</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DEVICE      illumigene® Group A Streptococcus</td><td rowspan=1 colspan=1>PREDICATEGEN-PROBE® Group A StreptococCus DirectK924715</td></tr><tr><td rowspan=1 colspan=1>Test Format</td><td rowspan=1 colspan=1>DNA Amplification Assay; Loop-MediatedIsothermal Amplification (LAMP)</td><td rowspan=1 colspan=1>Nucleic Acid Hybridization</td></tr><tr><td rowspan=1 colspan=1>Target SequencesDetected</td><td rowspan=1 colspan=1>206 base pair (bp) sequence S. pyogenes genome,resident in the pyrogenic exotoxin B (speB) gene</td><td rowspan=1 colspan=1>Streptococcus pyogenes ribosomal RNA</td></tr><tr><td rowspan=1 colspan=1>Reagents/Components</td><td rowspan=1 colspan=1>illumigene Sample Preparation ApparatusII/Negative Control IIiillumigene Group A Streptococcus Test Deviceillumigene Heat Treatment Tubes</td><td rowspan=1 colspan=1>•   Lysis Reagento  Probe ReagentHybridization BufferSelection ReagentPositive ControlNegative ControlSealing CardsPolypropylene Tubes</td></tr><tr><td rowspan=1 colspan=1>Amplification</td><td rowspan=1 colspan=1>Self contained and automated</td><td rowspan=1 colspan=1>Not Appliable</td></tr><tr><td rowspan=1 colspan=1>Testing Time</td><td rowspan=1 colspan=1>Less than 60 minutes</td><td rowspan=1 colspan=1>Less than 90 minutes</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>illumipro-10** Automated Isothermal Amplificationand Detection System</td><td rowspan=1 colspan=1>GEN-PROBE° LEADER® LuminOmetER</td></tr><tr><td rowspan=1 colspan=1>Reading Method</td><td rowspan=1 colspan=1>Visible Light Transmission</td><td rowspan=1 colspan=1>Chemiluminescent Emissions</td></tr><tr><td rowspan=1 colspan=1>PerformanceCharacteristics</td><td rowspan=1 colspan=1>Sensitivity: 98.0% [95% Cl: 93.1% - 99.5%]Specificity: 97.7% [95% CI: 96.3% - 98.6%]</td><td rowspan=1 colspan=1>Sensitivity: 94.1%Specificity: 98.3%</td></tr></table>

# K.Standard/Guidance Document Referenced (if applicable):

Ccal anLaboato Sanar tiUs roto orvalatio QualtativT e Approved Guideline- Second Edition (EP12-A)   
Cca anLaboratoy Standar stiue. 0.sVeriationPeoncor recisnnTr Approved Guideline- Second Edition (EP15-A2)   
lny Snarst0C G Second Edition (EP7-A2)

# L. Test Principle:

The ille rou tre sy basn o-edateral plation olgy ALomeat mplification  A s plishe y he ecially de prers hat provieec continuous isothermal amplification. Magnesium-pyrophosphate is produced as a by-product of LAMP n uha y etae roo u significant change in sample absorbance and is considered a negative reaction.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 illumigeno® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>Inspired Science. Trusted Sofutions.</td><td>Date:</td><td>September 10, 2012</td></tr></table>

# M. Performance Characteristics (if/when applicable):

Analytical Performance:

a. Precision/Reproducibility:

Blind-coded panels of 10 samples were supplied to three independent laboratories. Samples were randomly sorted within each panel to mask sample identities. The panels included contrived samples manufactured as low positive samples (i.e. limit of detection, $n = 3$ )and high negative samples $( n = 3 )$ .The panels also included contrived positive $( n = 3 )$ samples and natural negative samples $( n = 1 )$ Testing was performed by different operators at each site on the same ynt-assy arbilty)rs nassy vbilire ot ii G A Strep and five illumipro- 10instruments were used in this study. The results are given in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2      .</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>87/90</td><td rowspan=1 colspan=1>96.7%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

b. Linearity/assay reportable range:

Not applicable as this assay is qualitative c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Stability:

Sample storage and hold time studies were performed to characterize illumigene Group A Strep assay ranges. Validation studies performed at Meridian were completed using rayon swabs in both Liquid Amies (without charcoal) and Liquid Stuart Transport Medium.

Study results demonstrated that throat swab samples can be held at 21-27 C for up to 48 hours or at 2-8 C for up to 7 days prior to testing. Samples diluted in the illumigene Sample Preparation Apparatus can be held at 2-29 C for up to 2 hours prior to heat treatment. Heattreated samples may be held at 21-29 C for up to one hour prior to testing.

Final testing demonstrated that rayon, polyester and flocked nylon swab types with either Liquid Amies (without charcoal) or Liquid Stuart Transport Medium perform acceptably with the illumigene Group A Strep assay. Swab and transport medium types with demonstrated performance in the illumigene Group A Strep assay appear in the Package Insert.

# d. Detection limit:

Sensitivity studies were designed to determine the analytical limit of detection of S. pyogenes in throat swab specimens. Two common strains of S. pyogenes, ATCC 12344 and ATCC 19615, were evaluated with the illumigene Group A Strep assay. Each strain was spiked into sterile saline and diluted serially. Dilutions were combined with negative matrix (rayon swabs inoculated with normal throat flora screened negative for S. pyogenes, and Liquid Amies (without charcoal) Transport Media) prior to testing. A minimum of twenty replicates for each dilution were individually processed and tested to establish limit of detect. Testing was performed using three production lots of illumigene Group A Strep and six illumipro- 1Oinstruments. External Positive and Negative Controls were tested each day throughout the study. The Limit of Detection for the assay was reported as 400 CFU/Test for ATCC 12344 and 430 CFU/Test for ATCC 19615.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 (llumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>nred Sci. ru S</td><td>Date:</td><td>September 10, 2012</td></tr></table>

The following S. pyogenes strains were tested and produced positive reactions at or below stated assay limit of detect of 400 CFU/Test with illumigene Group A Strep: ATCC 12384, NCIMB 13285, CCUG 33061, CCUG 33409, CCUG 39158, ATCC 49399, CCUG 53553.

Limit of Detection studies are acceptable.

# e. Analytical specificity:

# Interference Testing:

Interfering substance testing was performed to assess the potential impact of non-microbial contaminants expected to be present in throat swab samples on illumigene Group A Strep test results. Potentially interfering substances were tested with negative and contrived positive (ATCC 12344, ATCC 19615) samples. Contrived positive samples were prepared near the reported limit of detection for each strain tested. Negative samples and contrived positive samples were added to the illumigene Sample Preparation Apparatus II and inoculated with throat swab matrix (rayon swab inoculated with normal throat flora, screened negative for Streptococcus pyogenes, and Liquid Amies Transport Medium). Each inoculated sample was tested in triplicate.

The following biological substances, at the saturated solvent/diluent concentrations indicated, do not interfere with test results: Mucus $( 5 . 0 \mathrm { m g / m L } )$ , Human saliva $\{ 1 0 \% \lor / \lor \} ,$ and Whole Blood $( 2 . 5 \% \ v / v )$ . Whole Blood at concentrations greater than $2 . 5 \%$ v/v may interfere with the illumigene Group A Strep Assay.

The following chemical substances, at the saturated solvent/diluents concentrations indicated, do not interfere with test results: Acetaminophen $( 1 9 . 5 ~ \mathrm { m g / m L } )$ , Aspirin $( 1 2 . 3 ~ \mathrm { m g / m L } )$ , Cepacol Mouthwash, [Cetyopridinium Chloride $ 0 . 0 0 5 \% \quad \mathsf { v } / \mathsf { v }  \}$ , Cepacol® Sore Throat Lozenges [Benzocaine $( 0 . 0 9 \mathrm { \ m g / m L } )$ ,Menthol $\{ 0 . 0 2 \ m g / \ m \mathrm { L } \} .$ Chloraseptic® Oral Anesthetic/Analgesic [Phenol $( 0 . 0 7 \% \quad \mathsf { v } / \mathsf { v } ) ]$ ,Contac® Cold $^ { + }$ Flu Tablets [Acetaminophen $( 1 6 . 2 \quad { \mathfrak { m g } } / { \mathfrak { m L } } ) ,$ Chlorpheniramine maleate $\{ 0 . 0 6 ~ \mathrm { m g / m L } \}$ , Phenylephrine HCI $\{ 0 . 1 6 ~ \mathrm { m g / m L } \} ]$ ,Crest® Complete Toothpaste [Sodium fluoride $( 0 . 1 ~ \mathrm { m g / m L } ) ]$ , Diphenhydramine HCI $\smash { ( 2 . 7 \ m g / m L }$ $H A L L S ^ { \otimes }$ Cough Drops [Menthol $\{ 0 . 0 8 \ : \mathrm { \ m g / m L } \} ,$ Ibuprofen $( 1 5 . 6 ~ \mathrm { m g / m L } )$ , Listerine® Antiseptic Mouthwash [Eucalyptol $\{ 0 . 0 0 9 2 9 \mid \boldsymbol { \mathsf { v } } / \mathsf { v } \}$ ,Menthol $( 0 . 0 0 4 2 \% \ v / v )$ ,Methyl salicylate $\{ 0 . 0 0 6 0 \% \ v / v \}$ ,Thymol $\{ 0 . 0 0 6 4 \% \lor / { \mathsf { v } } \} ]$ , Robitussin® Cough/Chest Congestion Cough Syrup [Dextromethorphan HBr (0.2 $m \mathbf { g } / m L )$ , Guaifenesin $\left\{ 2 . 0 \mathrm { \ m g / m L } \right\}$ .

Zicam® Oral Mist [Zincum Aceticum 2X, Zincum Gluonicum 1X $( 0 . 6 2 5 \% \ v / v )$ produced invalid results in all replicates tested.

Interference studies are acceptable.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>Ipied ct</td><td>Date:</td><td>September 10, 2012</td></tr></table>

# Cross-Reactivity Study:

Potentially cross-reacting microorganisms expected to be present in throat swab specimens were added to negative and contrived positive samples. The negative sample was prepared from S. pyogenes negative clinical throat swab sample in Liquid Amies (without charcoal) Transport Medium. The contrived positive sample was prepared by spiking sterile saline with Streptococcus pyogenes, strain ATCC 12344 at approximately 400 CFU/Test, the reported limit of detection for the strain.

Potentially cross-reactive microorganisms were added at concentrations of $1 . 2 \times 1 0 ^ { 8 } ( F U / m L$ (bacteria and fungi); Human DNA was tested at $0 . 0 2 ~ \mathrm { m g / m L }$ .Dilution controls for each sample were prepared by adding sterile saline solution in place of the potentially cross-reactive microorganisms. Each sample was tested in triplicate. No microorganism tested met the definition of interferent or cross-reactive.

None of the following organisms reacted with illumigene Group A Strep: Acinetobacter baumannii, Acinetobacter Iwoffi, Aeromonas hydrophila, Arcanobacterium haemolyticum, Bordetella bronchiseptica, Bordetella holmesii, Bordetella parapertussis, Bordetella pertussis, Burkholderia cepacia, Campylobacter jejuni, Candida albicans, Citrobacter freundii, Corynebacterium diphtheria, Corynebacterium pseudodiphtheriticum, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenza, Klebsiella oxytoca, Klebsiella pneumoniae, Lactococcus lactis, Legionella jordanis, Legionella micdadei, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas fluorescens, Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus canis, Streptococcus dysgalactiae (subspecies equisimilis), Streptococcus equinus, Streptococcus intermedius, Streptococcus mitis, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus salivarius, Streptococcus suis, Streptococcus uberis, Streptococcus sp. Viridans type.

Mycoplasma pneumoniae was tested at $1 . 5 \times 1 0 ^ { 6 } ( F U / m l$ with no reaction with the illumigene Group A Strep assay.

Cross-reactivity studies are acceptable.

# f. Assay cut-off:

The illumigene Group A Strep assay has a fixed cut-off based on the measured change in light transmission at the assay endpoint. The illumipro- 1Omeasures transmission of light through the Test and the Control reactions at the start of the Assay Run (Signalnial) and at the end of the Assay Run (Signalinal). The illumipro- $1 0$ calculates the change in transmission between the Signalanal:Signalinitial and compares the result to a fixed cut-off value. Test results are reported as Positive or Negative based on comparison to the assay cut-off. Fixed cut-off values were based on well characterized clinical specimens.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td rowspan="2">pied Scine. Tus t</td><td>Date:</td><td></td></tr><tr><td></td><td>September 10, 2012</td></tr></table>

2. Comparison Studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

Clinical Studies:

a. Clinical Sensitivity:

Cinical trials for the illumigene Group A Streptococcus (Group A Strep) DNA Amplification Assay, including the illumipro- $1 0$ Automated Isothermal amplification and detection system, were conducted from April to June 2012. Performance characteristics of the assay were determined by comparison to composite bacterial culture method for Group A Streptococcus. A total of 798 qualified specimens were evaluated with the test; two specimens produced initial invalid results which were negative upon retest. Overall assay Sensitivity was reported as $9 8 . 0 \%$ $9 5 \%$ Cl: $9 3 . 1 \sim$ $9 9 . 5 \% ] .$ ;overall assay Specificity was reported as $9 7 . 7 \%$ $1 9 5 \%$ Cl: $9 6 . 3 \textrm { -- } 9 8 . 6 \% ]$ ; overall assay Invalid Rate was $0 . 3 \%$ $1 9 5 \%$ Cl: $0 . 1 - 0 . 9 \% ]$ . Compiled clinical study information is described below:

Table 1: illumigene Group A Strep Performance Data Summary   

<table><tr><td rowspan=2 colspan=1>Group A StreptococcusComposite Culture</td><td rowspan=1 colspan=3>illumigene Group A Strep</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>680*</td><td rowspan=1 colspan=1>696</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>682</td><td rowspan=1 colspan=1>798</td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>100/102</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>93.1 - 99.5%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>680/696</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>96.3 - 98.6%</td></tr><tr><td rowspan=1 colspan=1>Invalid Rate</td><td rowspan=1 colspan=1>2/800</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.1 - 0.9%</td></tr></table>

Tw specimens producd initial invalid results that were negative upon re-test.A total  798 qualifd specimens were evaluated with the test device and composite bacterial culture methods.

Three independent clinical test sites located in the Midwestern and Southern regions of the United States participated in the device evaluation. All samples utilized in the study were leftover human specimens, not individually identifiable. All samples included in the study were submitted to the testing laboratory by an ordering physician for Group A Streptococcus testing and were presumed from symptomatic patients. No restrictions were placed on age, gender, medications or known pharmaceutical therapies.

Composite culture methods were employed to accommodate reports that Group A Streptococcus culture is considered $9 0 \ - \ 9 5 \%$ sensitive when correct sampling and plating techniques are used. 12 The Composite Culture Method consisted of the Clinical Site Culture Method as performed in standard of care testing and a Reference Culture Method performed by

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K122019 illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. d </td><td>Attachment Description: Date:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td></td><td>September 10, 2012</td></tr></table>

Meridian Bioscience. Site culture testing was performed by direct plating of the throat swab specimen while reference culture testing was performed by plating the swab transport media. Specimens producing positive Group A Streptococcus results from either the Site Culture Method or the Reference Culture Method were considered positive.

Specimens that generated invalid results were further evaluated. Data review for the two initial invalid samples revealed one Control Chamber failure and one suspect Test Chamber reaction. Repeat testing for both specimens produced valid, negative results. Site performance information was analyzed by Composite Culture Reference Testing and Site Culture Methods. Site performance as compared to Composite Culture Method, is summarized in Table 2. Site performance as compared to Site Culture Methods is presented in Table 3.

Table 2: illumigene Group A Strep Assay Performance by Site; Composite Culture Method   

<table><tr><td rowspan=2 colspan=1>SiteIdentification</td><td rowspan=1 colspan=3>Positive Specimens       </td><td rowspan=1 colspan=3>&quot;Negative Specimens</td><td rowspan=1 colspan=2>Invalid Specimens</td></tr><tr><td rowspan=1 colspan=1>illumigene/CompositeCulture</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene/CompositeCulture</td><td rowspan=1 colspan=1>%Specificity</td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1>Invalid/Total</td><td rowspan=1 colspan=1>%Invalid</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100/102</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>93.1 -99.5%</td><td rowspan=1 colspan=1>680/696</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>96.3 -98.6%</td><td rowspan=1 colspan=1>2/800</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>47/47</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>92.4 - 100.0%</td><td rowspan=1 colspan=1>287/291</td><td rowspan=1 colspan=1>98.6%</td><td rowspan=1 colspan=1>96.5 - 99.5%</td><td rowspan=1 colspan=1>0/338</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>78.7-98.2%</td><td rowspan=1 colspan=1>204/212</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>92.7-98.1%</td><td rowspan=1 colspan=1>1/243</td><td rowspan=1 colspan=1>0.4%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>25/25</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>86.7 - 100.0%</td><td rowspan=1 colspan=1>189/193</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>94.8 - 99.2%</td><td rowspan=1 colspan=1>1/219</td><td rowspan=1 colspan=1>0.5%</td></tr></table>

Table 3: illumigene Group A Strep Assay Performance by Site; Clinical Site Culture Method   

<table><tr><td rowspan=2 colspan=1>SiteIdentification</td><td rowspan=1 colspan=3>Positive Specimens</td><td rowspan=1 colspan=3>2                                  &quot;Negative Specimens</td><td rowspan=1 colspan=2>Invalid Specimens</td></tr><tr><td rowspan=1 colspan=1>illumigene/CompositeCulture</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene/CompositeCulture</td><td rowspan=1 colspan=1>%Specificity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Invalid/Total</td><td rowspan=1 colspan=1>%Invalid:</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>74/74</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.1 - 100.0%</td><td rowspan=1 colspan=1>682/724</td><td rowspan=1 colspan=1>94.2%</td><td rowspan=1 colspan=1>92.3-95.7%</td><td rowspan=1 colspan=1>2/800</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>40/40</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>91.2 - 100.0%</td><td rowspan=1 colspan=1>287/298</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>93.5 - 97.9%</td><td rowspan=1 colspan=1>0/338</td><td rowspan=1 colspan=1>. 0.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>18/18</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>82.4-100.0%</td><td rowspan=1 colspan=1>206/224</td><td rowspan=1 colspan=1>92.0%</td><td rowspan=1 colspan=1>87.7 - 94.9%</td><td rowspan=1 colspan=1>1/243</td><td rowspan=1 colspan=1>0.4%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>16/16</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>80.6 - 100.0%</td><td rowspan=1 colspan=1>189/202</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>89.3 - 96.2%</td><td rowspan=1 colspan=1>1/219</td><td rowspan=1 colspan=1>0.5%</td></tr></table>

Seven of the 102 Composite Culture-positive specimens were positive by Site Culture methods only; 26 of the 102 Composite Culture-positive specimens were positive only by the Reference Culture method; the two illumigene false-negative results were positive only by the Reference Culture performed by Meridian Bioscience. Statistical analysis of Site performance data was performed with no significant difference among Sites identified.

Clinical performance data was evaluated by patient age and gender. Seventy two $( 9 . 0 \% )$ patients tested were two years of age or younger; 385 $( 4 8 . 2 \% )$ patients were between two and 12 years of age; while 259 $( 3 2 . 5 \% )$ patients were greater than 12 and less than 21 years of age. The remaining 82 $( 1 0 . 3 \% )$ study patients were greater than 21 years old. Age information was known for all patients included in the performance analysis. No performance differences were noted based on chronological age. The study population included 410 $( 5 1 . 4 \% )$ female patients and 386 $( 4 8 . 4 \% )$ male patients. Gender was unknown for two $( 0 . 2 \% )$ of the study participants. No performance differences were noted based on gender.

<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">K122019 Ilumigene® Group A Streptococcus (Group A Strep) DNA AmpllfIcation Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>Inpd Science. s oli.</td><td>Date:</td><td>September 10, 2012</td></tr></table>

# References:

1. Diagnosis and Tretament of Streptococcal Phayrngitis. Beth A. Choby, MD. Volume 79, Number 5. March 1, 2009, American Family Physician, pp. 383-390.   
2. Pediatrics, American Academy of. Group A Streptococcal Infections. Pickering LK. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL : American Academy of Pediatrics, 29th ed., 2012, pp. 669-680.

b. Clinical Specificity: See Section 3a C. Other Clinical Supportive Data Not applicable

4Clinical cut-off: Not applicable

5. Expected values/Reference range: Overall incidence of Streptococcus pyogenes in patients tested during the 2012 clinical study was $1 4 . 6 \%$ EMPY (116/796).

N. Other Supportive Device and Instrument Information: Instrument: illumipro-10™

# O. System Descriptions:

System Description was reviewed in previous submission, K100818, K110012, K112125 and K121044. No system r software changes were made for the illumigene Group A Streptococcus assay.

Modes of Operation:

The illumipro- $10 ^ { \circ }$ heats each illumigene Group A Strep Test Device containing prepared samples and Control Reagent, facilitating amplification of target DNA. When S. pyogenes is present in the throat swab sample, a conserved sequence of the S. pyogenes is amplified and magnesium pyrophosphate is generated. Magnesm pyrohosphators  precipitate eactionmixure.Te illmirdetect he n in light transmission through the reaction mixture created by the precipitating magnesim pyrophosate. Sample results are reported as Positive or Negative based on the detected change in light transmission.

<table><tr><td rowspan="2">Meridian </td><td colspan="2">K122019 Illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inpired Scine. T Soio</td><td>Attachment Description:</td><td>510(k) Substantial Equivalence Determination Decision Summary</td></tr><tr><td>Date:</td><td>September 10, 2012</td></tr></table>

# . Software:

FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes_ X No_

3. Specimen Identification:

The illumipro1utilizes software to autoate incubation and detection f illumigene Molecular Diagostic ivi diaosic  reacns. The ilireports sampe resul s IVAL, OSTVE r NEG.

4. Specimen Sampling and Handling: Specimens are prepared manually. Incubation and detection are automated using the illumipro-10

5. Calibration: Calibration of the illumipro- 1Ois not required.

Quality Control:

The illue GroupStre Extenal Control K ncues  ositiv ControlReagent.he xternal Control is used in conjunction with the illumigene Sample Preparation Apparatus Il/Negative Control provided in the illumigene Group  Strep DNA Amplification Assay. External Control reagents are provided to aid theuser in detection of reagent deterioration, adverse environmental or test conditions, or varince in rato pera hat may ead  testerros.Te illi Grou  treExteal Conol  s required for routine Quality Control.

Meridian Biosciences, Inc. c/o Michelle L. Smith 3471 River Hills Drive Cincinnati, OH, 45244, US

Re: k122019 Trade Name: illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay illumigene® Group A Streptococcus (Group A Strep) External Control Kit Regulation Number: 21 CFR §866.3740 Regulation Name: Group A Streptococcus spp. Nucleic Acid Amplification Assay Regulatory Class: Class I Product Codes: OYZ, OOI Dated: September 10, 2012 Received: September 11, 2012

Dear Ms. Smith

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

# Page 2 - Michelle L. Smith

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, fagartro

Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication(s) for Use Form

510(k) Number: K122019

Device Name: illumigene® Group A Streptococcus (Group A Strep) DNA Amplification Assay

Indications for Use:

The illumigene $\textsuperscript { \textregistered }$ Group A Streptococcus (Group A Strep) assay, performed on the illumipro- $I 0 ^ { \mathbf { r m } }$ , is a qualitative in vitro diagnostic test for the detection of Streptococcus pyogenes (Group A $\beta$ -hemolytic Streptococcus) in throat swab specimens.

The illumigene Group A Strep assay utilizes loop-mediated isothermal DNA amplification (LAMP) technology to detect Streptococcus pyogenes by targeting a segment of the Streptococcus pyogenes genome. Results from the illumigene Group A Strep assay can be used as an aid in the diagnosis of Group A Streptococcal pharyngitis. The assay is not intended to monitor treatment for Group A Streptococcus infections.

illumigene Group A Strep is intended for use in hospital, reference or state laboratory settings. The device is not intended for point of-care use.

Prescription Use X_Over-The-Counter Use (Part 21 CFR 801 Subpart D) AND/OR (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Office of In Vitro Diagnostic Device Evaluation and Safety